Type to search

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China | Pharmtech Focus
Jubilant Therapeutics Inc. Announces US FDA Clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for Treatment of Solid Tumors With Brain Metastases and Primary Brain Tumors | Pharmtech Focus
H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials | Pharmtech Focus